71 completed, 28 unknown, 22 recruiting, 21 terminated. 86 Phase 2, 55 Phase 3, 28 Phase 1, 9 Not applicable, 4 Phase 4.
Follow pegaspargase: new trials by email Literature Review of pegaspargase trials Research Report on pegaspargase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma Gemcitabine (GEM), Etoposide Injection, Dexamethasone - Natural Killer/T-cell Lymphoma | Phase 2 | Not yet recruiting | Fudan University | 620 | 2026-09-01 | 2026-08-17 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma Pegaspargase (PEG) Asparaginase, Gemcitabine (GEM), Oxaliplatin - Extranodal NK/T-cell Lymphoma | Phase 2 | Not yet recruiting | Beijing Tongren Hospital | 34 | 2026-05-15 | 2026-04-28 |
| A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma Sintilimab, Pegaspargase, Selinexor - NKTCL | Phase 2 | Not yet recruiting | Sun Yat-sen University | 47 | 2026-05-06 | 2026-05-08 |
| ALL Backbone in AYAs Blinatumomab, Oncaspar, Cyclophosphamide - Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 67 | 2026-04-03 | 2026-08-17 |
| Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase - Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH) | Phase 1 / Phase 2 | Recruiting | Beijing Tongren Hospital | 25 | 2026-04-01 | 2026-04-13 |
| Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL Golidocitinib + Pegaspargase + Anti-PD-1 mAb - NK T-Cell Lymphoma | Phase 2 | Not yet recruiting | LIANG WANG | 40 | 2026-02-10 | 2026-03-09 |
| A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias JNJ-75276617, Fludarabine, Cytarabine - Acute Leukemias, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2025-12-26 | 2025-06-22 | |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-21 |
| Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma Sintilimab with P-GEMOX Regimen, P-GEMOX Regimen - Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Phase 2 | Recruiting | Sun Yat-sen University | 84 | 2024-10-22 | 2026-04-14 |
| Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL Dexamethasone, Blinatumomab, Venetoclax - Precursor B-Cell Lymphoblastic Leukemia | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 20 | 2024-08-15 | 2024-08-15 |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-09 | 2024-05-17 | |
| Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma Linperlisib, Camrelizumab, Pegaspargase - Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma | Phase 1 / Phase 2 | Recruiting | Beijing Tongren Hospital | 43 | 2024-04-14 | 2024-04-19 |
| Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia Bortezomib - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 2 | Recruiting | Instituto do Cancer do Estado de São Paulo | 50 | 2024-04-01 | 2025-05-16 |
| The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma chidamide, anti-PD1 antibody, and pegaspargase, DDGP - Extranodal Natural Killer T Cell Lymphoma | Phase 3 | Not yet recruiting | Ruijin Hospital | 142 | 2024-02-15 | 2024-02-13 |
| PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma 4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase, 2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase - NK-T-Cell Lymphoma, Extranodal | Not applicable | Recruiting | Ruijin Hospital | 89 | 2023-12-06 | 2026-01-27 |
| A Study of PD5K3 in Healthy Adult Volunteers PD5K3, Placebo, Pegaspargase - Lymphoblastic Leukemia, Acute, Lymphoblastic Lymphoma | Phase 1 | Completed | Chongqing Peg-Bio Biopharm Co., Ltd. | 28 | 2023-11-27 | 2024-07-30 |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Dexamethasone, Mitoxantrone, PEG asparaginase - Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Tanja Andrea Gruber | 90 | 2023-11-03 | 2026-06-03 |
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil Prednisone, Vincristin, Daunorubicin - Acute Lymphoid Leukemia, Minimal Residual Disease | Recruiting | Instituto do Cancer do Estado de São Paulo | 180 | 2023-09-05 | 2025-05-07 |
Showing 20 of 168. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (90) · Leukemia (45) · Lymphoma, Extranodal NK-T-Cell (25) · Burkitt Lymphoma (19) · Lymphoma (12) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (12) · Leukemia, Biphenotypic, Acute (9) · Recurrence (9) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (6) · Lymphohistiocytosis, Hemophagocytic (5) · Leukemia, T-Cell (4) · Down Syndrome (3) · Leukemia, Myeloid, Acute (3) · Lymphoma, T-Cell (3) · Neoplasms (3)
Children's Oncology Group (25) · National Cancer Institute (NCI) (17) · Sun Yat-sen University (13) · St. Jude Children's Research Hospital (12) · Dana-Farber Cancer Institute (7) · M.D. Anderson Cancer Center (7) · Beijing Tongren Hospital (6) · Ruijin Hospital (5) · Therapeutic Advances in Childhood Leukemia Consortium (4) · Memorial Sloan Kettering Cancer Center (3) · Alliance for Clinical Trials in Oncology (2) · Amgen (2) · Beijing Friendship Hospital (2) · Children's Cancer Group, China (2) · Fudan University (2)
United States (94) · China (46) · Canada (42) · Australia (38) · Puerto Rico (17) · Switzerland (15) · New Zealand (14) · Germany (13) · Italy (9) · Netherlands (9) · France (8) · Israel (8) · Austria (7) · Czechia (7) · Sweden (7)
Sima Jeha, MD (6) · Elizabeth Raetz, MD (3) · Rong Tao, MD (3) · Anne L Angiolillo (2) · Hua Wang, MD. (2) · Liang Wang (2) · Liang Wang, M.D. (2) · Wenqi Jiang, MD (2) · Adele K. Fielding (1) · Albert Assad, MD (1) · Allen Eng Juh Yeoh, MBBS (1) · Amir Fathi, MD (1)
PMID 41671463, PMID 39121442, PMID 37890117, PMID 38446568, PMID 33242441, PMID 16421426, PMID 19433688, PMID 23007406, PMID 23233662, PMID 24970932, PMID 26590194, PMID 29284596, PMID 30138085, PMID 30957229, PMID 31188727, PMID 31612640, PMID 32552472, PMID 32589970, PMID 33152759, PMID 33496745, PMID 34806163, PMID 35271306, PMID 35622074, PMID 36603187, PMID 39316653, PMID 40315406, PMID 40908865, PMID 42085640, PMID 42477805, PMID 10499612, PMID 10627444, PMID 11426549, PMID 12011123, PMID 12111109, PMID 12153596, PMID 12694250, PMID 12780755, PMID 15087948, PMID 15154634, PMID 15368546, PMID 15801953, PMID 15952999, PMID 16105981, PMID 16556894, PMID 16609069, PMID 17003366, PMID 17761975, PMID 18039957, PMID 18089878, PMID 18648353
U10CA098543 (18), U10CA180886 (16), 2017 (3), 2009 (2), 2014 (2), F32CA141762 (2), R37CA036401 (2), 2005 (1), 2018 (1), 2019 (1), P01CA068484 (1), P30CA006516 (1), P30CA008748 (1), P30CA021765 (1), P30CA033572 (1)